Evidence map›Paper›PMID 28137726›Full record

ArticleBrain : a journal of neurology2017

Molecular analyses of neurogenic defects in a human pluripotent stem cell model of fragile X syndrome.

Michael J Boland, Kristopher L Nazor, Ha T Tran, Attila Szücs, Candace L Lynch, Ryder Paredes, Flora Tassone, Pietro Paolo Sanna, Randi J Hagerman, Jeanne F Loring

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Modelling the Human Blood-Brain Barrier in Huntington Disease.International journal of molecular sciences · 2022
    Article
  12. Article
  13. Article
  14. Review
  15. Dysregulation of BMP, Wnt, and Insulin Signaling in Fragile X Syndrome.Frontiers in cell and developmental biology · 2022
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Michael J BolandDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA.
Kristopher L NazorDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA.
Ha T TranDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA.
Attila SzücsBioCircuits Institute, University of California San Diego, La Jolla, CA, USA.
Candace L LynchDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA.
Ryder ParedesCIRM Bridges to Stem Cells Program, California State University Channel Islands, Camarillo, CA, USA.
Flora TassoneDepartment of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA, USA.
Pietro Paolo SannaDepartment of Molecular and Cellular Neuroscience, The Scripps Research Institute, La Jolla, CA, USA.
Randi J HagermanMIND Institute, University of California Davis, Sacramento, CA, USA.
Jeanne F LoringDepartment of Chemical Physiology, The Scripps Research Institute, La Jolla, CA, USA.
Scripps Research Institute · USCalifornia State University, Channel Islands · USEötvös Loránd University · HUUniversity of California, Davis · USUniversity of California Davis Medical Center · US

Funding

Restoring FMRP Phenotypes Frpm Temporal Regional and Splice- Isoforms VarationsP30HD002274 · NICHD · UNIVERSITY OF WASHINGTON · PI GURALNICK, MICHAEL J · 1985 to 2013
$33.6M
Intellectual and Developmental Disabilities Research CenterU54HD083091 · NICHD · UNIVERSITY OF WASHINGTON · PI GURALNICK, MICHAEL J · 2014 to 2019
$7.9M
Epigenetic regulation of the FMR1 geneR01GM113929 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEDIN, FREDERIC LOUIS, HAGERMAN, PAUL J · 2015 to 2018
$1.9M
Autism iPSCs for Studying Function and Dysfunction in Human Neural DevelopmentR33MH087925 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI LORING, JEANNE F · 2011 to 2012
$942k
Dopaminergic Neurons from Pluripotent Stem Cells for Substance Abuse ResearchR21DA032975 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI LORING, JEANNE F, SANNA, PIETRO P · 2011 to 2012
$521k
NCATS NIH HHS L30 TR001250NICHD NIH HHS P30 HD002274NICHD NIH HHS U54 HD083091NIDA NIH HHS R21 DA032975NIGMS NIH HHS R01 GM113929NIMH NIH HHS R33 MH087925
6 · The paper itself

Abstract

New research suggests that common pathways are altered in many neurodevelopmental disorders including autism spectrum disorder; however, little is known about early molecular events that contribute to the pathology of these diseases. The study of monogenic, neurodevelopmental disorders with a high incidence of autistic behaviours, such as fragile X syndrome, has the potential to identify genes and pathways that are dysregulated in autism spectrum disorder as well as fragile X syndrome. In vitro generation of human disease-relevant cell types provides the ability to investigate aspects of disease that are impossible to study in patients or animal models. Differentiation of human pluripotent stem cells recapitulates development of the neocortex, an area affected in both fragile X syndrome and autism spectrum disorder. We have generated induced human pluripotent stem cells from several individuals clinically diagnosed with fragile X syndrome and autism spectrum disorder. When differentiated to dorsal forebrain cell fates, our fragile X syndrome human pluripotent stem cell lines exhibited reproducible aberrant neurogenic phenotypes. Using global gene expression and DNA methylation profiling, we have analysed the early stages of neurogenesis in fragile X syndrome human pluripotent stem cells. We discovered aberrant DNA methylation patterns at specific genomic regions in fragile X syndrome cells, and identified dysregulated gene- and network-level correlates of fragile X syndrome that are associated with developmental signalling, cell migration, and neuronal maturation. Integration of our gene expression and epigenetic analysis identified altered epigenetic-mediated transcriptional regulation of a distinct set of genes in fragile X syndrome. These fragile X syndrome-aberrant networks are significantly enriched for genes associated with autism spectrum disorder, giving support to the idea that underlying similarities exist among these neurodevelopmental diseases.

Indexed as

Models, BiologicalAnimalsAutism Spectrum DisorderCell DifferentiationCell MovementCells, CulturedDNA MethylationFetusFragile X Messenger Ribonucleoprotein 1Fragile X SyndromeGene Expression RegulationGene Regulatory NetworksHumansMaleMiceNeurogenesisFMR1 protein, humanFragile X Messenger Ribonucleoprotein 1autism spectrum disorderbrain developmentfragile X syndromeneurogenesisstem cells

Identifiers

PMID28137726
PMCPMC5837342
OpenAlexW2580990738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.